Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Proteomics analysis revealed the therapeutic role of adipose-derived mesenchymal stem cells on radiation-induced colorectal fibrosis in rats.

Thandar M., Zhang L., Yang X., Chi P., Li Y.

Animal Study on Face & Skin, published in Biomed Pharmacother (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomed Pharmacother (2024)
Country
France
Reported sample size
—
Source database
PubMed
PMID
39693908
DOI
10.1016/j.biopha.2024.117763

Abstract (original English)

Background Radiation-induced colorectal fibrosis (RICF) is a chronic condition that can develop after pelvic radiation therapy for colorectal cancer. Adipose-derived mesenchymal stem cells (ADSCs) have emerged as promising candidate for fibrosis treatment, yet the mode of action of ADSC upon RICF remains obscure. This study aimed to investigate the optimal delivery route, treatment timing, anti-fibrotic effects, and underlying mechanisms of ADSCs upon RICF. Methods The RICF rat model was constructed by single dose of 20 Gy irradiation, and ADSCs were delivered via diverse ways (e.g., tail vein injection, abdominal aorta injection, peritoneal injection, or perianal tissue injection) at different frequencies (once, twice, or thrice a week) for 10 weeks. TMT-labelled proteomic and phosphoproteomic analysis was conducted for dissecting the underlying mechanisms of ADSCs upon RICF. ADSCs were co-cultured with primary human intestinal fibroblasts to verify the anti-fibrotic effects upon radiation-induced fibroblasts. Additionally, 4D label-free proteomic analysis and 4D-parallel reaction monitoring were carried out to explore their molecular mechanisms. Results RICF rats revealed better outcomes after intraperitoneal injection of ADSCs rather than the relative ways, and in particular, those with thrice-weekly injections showed effective prevention and improvement in RICF. Proteomic a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsProteomicsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationFibrosisRatsAdipose TissueRats, Sprague-DawleyMaleHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research